Friday, 16 Feb 2018

You are here

Poor Prognosis of the MDA-5 Antibody in Dermatomyositis

Researchers from Hong Kong assessed the clinical associations seen with the anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) assay in consecutive patients with dermatomyositis (DM) and polymyositis (PM).

Twenty patients with either DM or PM who were followed in the Rheumatology Clinic of Kwong Wah Hospital, Hong Kong were recruited and underwent testing for the anti-MDA-5 antibody.

Anti-MDA5 Ab was found in 30% of patients with DM but not in DM patients. All patients with the antibody had clinically manifest amyopathic DM (CADM).  They were more likely to be male, younger and with shorter disease duration.

The MDA5 Ab profile identifies a subset of CADM with rapidly progressive interstitial lung disease (RP-ILD) and digital ulcers and was unaffected by treatment.

Another recent report from the American Journal of Medicine assayed 182 PM/DM patients for antiaminoacyl-tRNA synthetase (ARS) and MDA5 antibodies (Citation source https://buff.ly/2GC0EOG).

MDA-5 positive patients were more likely to have rapidly progressive ILD (RP-ILD) (55.8% vs. 25% versus 16.9%, P < 0.001) compared to those with ARS or without either antibody profile.

Whereas treatment responses and 5 year survival was poorest in the MDA5 group, the ARS patients had the best ILD improvement and survival (98% vs 50% in MDA5 group; P < 0.001).

MDA5-ILD patients are at risk for severe pulmonary manifestations, poor response to treatment and an unfavorable prognosis. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Nailfold Capillaroscopy Portends Prognosis in Systemic Sclerosis

Two reports underscore the importance of nailfold capillaroscopy (NFC) in scleroderma and have shown that nailfold capillary drop out was significantly associated with mortality in systemic sclerosis.

Inefficacy of Immunosuppressive Treatments in Systemic Sclerosis with ILD

EUSTAR study results published in Arthritis Research & Therapy show the current state of immunosuppressive use in systemic sclerosis patients with interstitial lung disease (SSc-ILD) to be ill-defined, but that liberal use of glucocorticoids (GC) in SSc-ILD should be discouraged.

ESRD Death Declines in Vasculitis Patients

 

In the past 2 decades, mortality from end-stage renal disease (ESRD) among U.S. patients with granulomatosis with polyangiitis (GPA) has declined significantly, a nationwide study found.

Stroke Risk Confirmed in SLE

The most common cerebrovascular events (CVEs) seen among a large cohort of patients with systemic lupus erythematosus (SLE) were stroke and transient ischemia, and the majority of these events were attributable to the disease itself, a multinational study determined.

Stem Cell Transplant Succeeds in Scleroderma

Myeloablative autologous stem cell transplantation was significantly more effective than 12 months of cyclophosphamide among patients with severe scleroderma, an open-label multicenter study found.